​

EyePoint Pharmaceuticals (EYPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EYPT Stock Forecast

EyePoint Pharmaceuticals (EYPT) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $18.29, with a high of $40.00 and a low of $4.00. This represents a 301.10% increase from the last price of $4.56.

- $8 $16 $24 $32 $40 High: $40 Avg: $18.29 Low: $4 Last Closed Price: $4.56

EYPT Stock Rating

EyePoint Pharmaceuticals stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (65.00%), 7 Hold (35.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 7 13 Strong Sell Sell Hold Buy Strong Buy

EYPT Price Target Upside V Benchmarks

TypeNameUpside
StockEyePoint Pharmaceuticals301.10%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4711
Avg Price Target$5.50$18.29$24.00
Last Closing Price$4.56$4.56$4.56
Upside/Downside20.61%301.10%426.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26175--13
Aug, 26311---14
Jul, 2639---12
Jun, 2639---12
May, 26310---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 02, 2026China Renaissance Securities (US) Inc.$4.00$4.58-12.66%-12.28%
Aug 18, 2026Chardan Capital$5.00$5.31-5.84%9.65%
Aug 18, 2026RBC Capital$5.00$4.872.67%9.65%
Aug 17, 2026Jefferies$8.00$4.6173.54%75.44%
Aug 06, 2026H.C. Wainwright$27.00$12.25120.41%492.11%
Jul 29, 2026Graig SuvannavejhMizuho Securities$39.00$11.96226.09%755.26%
Jul 15, 2026Annabel SamimyStifel Nicolaus$40.00$13.85188.81%777.19%
Feb 19, 2026Mizuho Securities$36.00$14.36150.70%689.47%
Feb 05, 2026Lisa WalterRBC Capital$39.00$13.22195.01%755.26%
Oct 29, 2025Graig SuvannavejhMizuho Securities$33.00$12.25169.39%623.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 02, 2026Cowen & Co.ReduceHolddowngrade
Sep 02, 2026Cowen & Co.Reducedowngrade
Aug 18, 2026H.C. WainwrightBuyNeutraldowngrade
Aug 18, 2026RBC CapitalOutperformSector Performdowngrade
Aug 17, 2026LaidlawBuyBuyhold
Aug 17, 2026GuggenheimBuyBuyhold
Aug 17, 2026JefferiesBuyBuyhold
Aug 17, 2026Cantor FitzgeraldNeutraldowngrade
Aug 05, 2026CitigroupBuyBuyhold
Feb 05, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.03$-2.74$-1.82$-2.32$-3.17---
Avg Forecast$-1.95$-2.19$-1.94$-2.17$-2.51$-2.82$-2.42$0.11
High Forecast$-0.86$-1.18$-1.80$-1.86$-2.05$-2.26$-1.37$0.22
Low Forecast$-2.94$-3.48$-2.16$-2.31$-3.04$-3.27$-3.45$0.01
Surprise %4.10%25.11%-6.19%6.91%26.29%---

Revenue Forecast

$0 $120M $240M $360M $480M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$36.94M$41.40M$46.02M$43.27M$31.37M---
Avg Forecast$35.19M$41.28M$40.74M$42.56M$17.58M$12.48M$58.91M$310.06M
High Forecast$48.88M$60.17M$45.92M$53.22M$31.73M$12.48M$60.44M$559.56M
Low Forecast$20.04M$26.63M$32.38M$37.34M$5.18M$12.48M$57.38M$91.30M
Surprise %4.97%0.31%12.96%1.68%78.45%---

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-58.42M$-102.25M$-70.80M$-130.87M$-231.96M---
Avg Forecast$-76.02M$-61.30M$-70.80M$-80.95M$-99.07M$-107.54M$-93.87M$4.12M
High Forecast$-33.47M$-49.04M$-56.64M$-72.22M$-79.87M$-88.02M$-53.36M$8.43M
Low Forecast$-114.47M$-73.56M$-84.95M$-89.68M$-118.26M$-127.06M$-134.38M$341.29K
Surprise %-23.15%66.81%-61.67%134.15%---

EYPT Forecast FAQ

Is EyePoint Pharmaceuticals stock a buy?

EyePoint Pharmaceuticals stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that EyePoint Pharmaceuticals is a favorable investment for most analysts.

What is EyePoint Pharmaceuticals's price target?

EyePoint Pharmaceuticals's price target, set by 20 Wall Street analysts, averages $18.29 over the next 12 months. The price target range spans from $4 at the low end to $40 at the high end, suggesting a potential 301.10% change from the previous closing price of $4.56.

How does EyePoint Pharmaceuticals stock forecast compare to its benchmarks?

EyePoint Pharmaceuticals's stock forecast shows a 301.10% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for EyePoint Pharmaceuticals over the past three months?

  • September 2026: 7.69% Strong Buy, 53.85% Buy, 38.46% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 21.43% Strong Buy, 78.57% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is EyePoint Pharmaceuticals’s EPS forecast?

EyePoint Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.82, marking a -11.04% decrease from the reported $-3.17 in 2025. Estimates for the following years are $-2.42 in 2027, and $0.11 in 2028.

What is EyePoint Pharmaceuticals’s revenue forecast?

EyePoint Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $12.48M, reflecting a -60.21% decrease from the reported $31.37M in 2025. The forecast for 2027 is $58.91M, and $310.06M for 2028.

What is EyePoint Pharmaceuticals’s net income forecast?

EyePoint Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-108M, representing a -53.64% decrease from the reported $-232M in 2025. Projections indicate $-93.87M in 2027, and $4.12M in 2028.